IgA vasculitis nephritis
Conditions
Interventions
Prospective Treatment Group:Taltzcept
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
5 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Age 5 - 18 years, no gender restriction; 2. Clinical history of allergic purpura with 24-hour urine protein quantification >0.5 g/1.73m^2/day; 3. Renal biopsy confirming pediatric IgAVN; 4. Disease onset <6 months; 5. Patient and family voluntarily participate in this study and sign informed consent;
Exclusion criteria
Exclusion criteria: 1. Exclusion criteria for the prospective treatment group: (1) Allergic to or unable to tolerate Taitaxip; (2) Patients with underlying diseases such as severe infections, immunodeficiency, or hematologic diseases; (3) Exclude patients with other concurrent kidney diseases (such as hereditary kidney diseases); (4) eGFR <60 ml/min/1.73m^2 at onset; (5) Use of other biologics within the past 6 months; (6) Poor compliance and inability to cooperate to complete the study. 2. Exclusion criteria for the historical control group: (1) Patients with underlying conditions such as severe infections, immunodeficiency, or hematological diseases; (2) Patients with other coexisting kidney diseases (such as hereditary kidney diseases); (3) eGFR < 60 ml/min/1.73m^2 at onset; (4) Use of other biologics within the past 6 months; (5) Poor compliance and inability to cooperate to complete the study; (6) Lack of important baseline data or data at 24 weeks of treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission rate of urinary protein at 24 weeks; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence rate of proteinuria within 24 weeks;Adverse event;Change in eGFR at 24 weeks of treatment;Remission rate of hematuria at 24 weeks of treatment;Cumulative dose of glucocorticoids; | — |
Countries
China
Contacts
Public ContactKe Xu
Peking University First Hospital
Outcome results
None listed